Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: LCZ696 matching placebo
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 454
- Registration Number
- NCT01692301
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT01691807
- Locations
- 🇺🇸
Novartis Investigative Site, Morgantown, West Virginia, United States
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
- Conditions
- Malignant PEComa (Perivascular Epithelioid Cell Tumors)
- Interventions
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01690871
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Cataluña, Spain
Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT01688882
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT01686932
- Locations
- 🇩🇪
Novartis Investigative Site, Wallerfing, Germany
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT01685138
- Locations
- 🇺🇸
Massachusetts General Hospital Mass Gen 5, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine Washington University (16), Saint Louis, Missouri, United States
🇺🇸U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office, Dallas, Texas, United States
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT01685060
- Locations
- 🇺🇸
City of Hope National Medical Center Dept of Oncology 2, Duarte, California, United States
🇺🇸University of California at San Diego, Moores Cancer Ctr SC, San Diego, California, United States
🇺🇸Stanford University Medical Center Stanford Cancer Center(2), Stanford, California, United States
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2016-03-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 614
- Registration Number
- NCT01682863
- Locations
- 🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT01681576
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 870
- Registration Number
- NCT01682083
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom